Marfil-Rivera A, Marfil-Garza BA, Ramírez-Monterrubio LE, Cantú-Moreno D, Quintanilla-Muñiz IJ

Language: Spanish
References: 23
Page: 21-28
PDF size: 214.44 Kb.

ABSTRACT

Introduction: There are no studies analyzing therapeutic practices of Mexican neurologists in the treatment of migraine. Objetive: To analyze therapeutic practices of neurologists in the treatment of migraine. Methods: We surveyed adult neurologists (AN) and pediatric neurologists (PN) in order to know their therapeutic practices, based on hypothetical clinical cases and direct questions on pharmacologic and non-pharmacologic treatment. Results: The response rate was 14% and 16% for AN and PN, respectively. A 56% of NA would use a triptan for a short-lasting episode (‹ 1 h). In all, 78% of PN would use analgesics for attacks lasting ‹ 1 h, and triptans or analgesics (both type of neurologists in 30%) for attacks lasting 1-4 h. Prophylactic drug use was as follows: topiramate (both AN and NP in 30%), propranolol (AN: 27%, PN: 15%), and calcium channel blockers (AN: 8%, PN: 22%). BonTA has been used by 27% of AN. Nonpharmacologic measures were widely used by both type of neurologists. Conclusions: The clinical practice of Mexican AN with respect to migraine treatment is similar to that of their counterparts around the world. It was observed an adoption of the use of clinical guidelines for AN to the clinical practice of PN.

REFERENCES

1. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58(6): 885-94.

2. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lantéri-Minet M, Lucas C, Pradalier A, Chazot G, El Hasnaoui A.Prevalence and clinical characteristics of migraine in France. Neurology. 2002 Jul 23;59(2):232-7.

3. Queiroz LP, Barea LM & Blank N. An epidemiological study of headache in Florianopolis, Brazil. Cephalalgia 2006; 26: 122-7. London.

4. Lipton RB, Bigal ME, Rush SR, Yenkosky JP, Liberman JN, Bartleson JD, Silberstein SD. Migraine practice patterns among neurologists. Neurology 2004 8; 62(11): 1926-31.

5. Stark RJ, Valenti L, Miller GC. Management of migraine in Australian general practice. Med J Aust 2007; 187(3): 142-6.

6. Soon YY, Siow HC, Tan CY. Assessment of migraineurs referred to a specialist headache clinic in Singapore: diagnosis, treatment strategies, outcomes, knowledge of migraine treatments and satisfaction. Cephalalgia 2005; 25(12): 1122-32.

7. Lu S-R, Wang S-J, Fuh J-L. The practice pattern of migraine management among neurologists in Taiwan. Cephalalgia 2006; 26: 310-13.

8. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 2003; 43(1): 14-8.

9. Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, Estevez E, et al. Clinical characteristics and patterns of medication use of migraneurs in Latin America from 12 cities in 6 countries. Headache 2005; 45(2): 103-4.

10. Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA & Zukerman E. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009.

11. Pradilla AG, Vesga ABE, León-Sarmiento FE. GENECO.National neuroepidemiological study in Colombia (EPINEURO). Rev Panam Salud Publica 2003; 14(2): 104-11. Spanish.

12. Marfil RA, Gil AM, Acevedo V. Comparison of treatment patterns in migraine in three medical centers. Rev Mex Neuroci 2003; 4(6):466. Spanish.

13. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78(17): 1346-53.

14. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate Pediatric Migraine Study Investigators.Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45(10): 1304-12.

15. Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007; 22(7): 829-35.

16. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63(12): 2215-24.

17. Eiland LS, Jenkins LS, Durham SH. Pediatric migraine: pharmacologic agents for prophylaxis. Ann Pharmacother 2007; 41(7): 1181-90.

18. Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM; BoNTA-009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007; 8(6): 478-85.

19. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM; BOTOX North American Episodic Migraine Study Group Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebocontrolled exploratory study. Headache 2007; 47(4): 486-99.

20. Silberstein SD. Preventive migraine treatment. Neurol Clin 2009; 27(2): 429-43.

21. Wöber C, Holzhammer J, Zeitlhofer J Wessely P, Wöber-Bingöl C. Trigger factors of migraine and tension-type headache: experience and knowledge of the patients. J Headache Pain 2006; 7(4): 188-95.

22. Evans RW, Lipton R, Ritz KA. A Survey of Neurologists on Self-treatment and Treatment of Their Families. Headache 2007; 47: 58-64.

23. Jelinski SE, Becker WJ, Christie SN, Giammarco R, Mackie GF, Gawel MJ, Eloff AG, Magnusson JE. Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia 2006; 26: 578-88.